Primary insider trading
Reference is made to the stock exchange announcement made by Thor Medical ASA (the "Company") the Company on 21 April 2024 regarding issuance of shares to members of the board of directors by exercise of vested RSUs, as well as stock exchange announcement on 2 May 2024 regarding registration of the share capital increase.
Board member and primary insider of the Company, John Andersen, received 416,990 shares in connection with the exercise of RSUs. John Andersen has now transferred all 416,990 shares to Scatec Innovation AS where John Andersen is the CEO, being a close associate of a primary insider of the Company. Primary insider notifications pursuant to the market abuse regulation article 19 are attached.
Disclosure regulation
This information is required to be disclosed under Section 5-12 of the Securities Trading Act.
Contacts
About Thor Medical ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
To learn more, visit www.thormedical.no.
Attachments
Subscribe to our company announcements
Keep up to date with our company announcements by subscribing.
Visit our pressroom and see more company announcements from us.
Our pressroom